Insulet (NASDAQ:PODD) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Insulet (NASDAQ:PODD) from a buy rating to a strong-buy rating in a research report released on Saturday.

Several other research firms also recently weighed in on PODD. Oppenheimer reduced their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday. BTIG Research reduced their target price on shares of Insulet from $320.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday. Barclays reduced their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday. Raymond James Financial reduced their price objective on shares of Insulet from $355.00 to $263.00 in a research note on Thursday. Finally, Truist Financial dropped their target price on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday. Eighteen research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $257.09.

Insulet Price Performance

PODD opened at $154.16 on Friday. The company has a market capitalization of $10.68 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 0.88 and a beta of 1.20. The company has a quick ratio of 2.15, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $211.22 and a 200-day moving average price of $263.85. Insulet has a twelve month low of $148.30 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s revenue was up 33.9% on a year-over-year basis. During the same quarter last year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet will post 6.43 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock worth $2,715,651,000 after acquiring an additional 87,845 shares during the last quarter. State Street Corp lifted its holdings in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after acquiring an additional 41,019 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after acquiring an additional 141,167 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Insulet in the 4th quarter worth approximately $300,794,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.